

# Product datasheet for TR506257

## Cpeb3 Mouse shRNA Plasmid (Locus ID 208922)

### **Product data:**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	Cpeb3 Mouse shRNA Plasmid (Locus ID 208922)
Locus ID:	208922
Synonyms:	4831444O18Rik; CPE-BP3; mKIAA0940
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	Cpeb3 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 208922). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<u>BC128377, NM 001290826, NM 001290827, NM 001290828, NM 001290829, NM 198300, NM 198300.1, NM 198300.2, NM 198300.3, NM 001290829.1, NM 001290828.1, NM 001290826.1, NM 001290827.1</u>
UniProt ID:	<u>Q7TN99</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

#### **CRIGENE** Cpeb3 Mouse shRNA Plasmid (Locus ID 208922) – TR506257

Summary: Sequence-specific RNA-binding protein which acts as a translational repressor in the basal unstimulated state but, following neuronal stimulation, acts as a translational activator (PubMed:17024188, PubMed:26074072). In contrast to CPEB1, does not bind to the cytoplasmic polyadenylation element (CPE), a uridine-rich sequence element within the mRNA 3' UTR, but binds to a U-rich loop within a stem-loop structure (PubMed:17024188). Required for the consolidation and maintenance of hippocampal-based long term memory (PubMed:26074003). In the basal state, binds to the mRNA 3' UTR of the glutamate receptors GRIA1 and GRIA2 and negatively regulates their translation (PubMed:17024188, PubMed:22153079). Also represses the translation of DLG4, GRIN1 GRIN2A and GRIN2B (PubMed:24155305). When activated, acts as a translational activator of GRIA1 and GRIA2 (PubMed:22153079, PubMed:26074003). In the basal state, suppresses SUMO2 translation but activates it following neuronal stimulation (PubMed:26074071). Binds to the 3' UTR of TRPV1 mRNA and represses TRPV1 translation which is required to maintain normal thermoception (PubMed:26915043). Binds actin mRNA, leading to actin translational repression in the basal state and to translational activation following neuronal stimulation (PubMed:26074072). Negatively regulates target mRNA levels by binding to TOB1 which recruits CNOT7/CAF1 to a ternary complex and this leads to target mRNA deadenylation and decay (By similarity). In addition to its role in translation, binds to and inhibits the transcriptional activation activity of STAT5B without affecting its dimerization or DNA-binding activity. This, in turn, represses transcription of the STAT5B target gene EGFR which has been shown to play a role in enhancing learning and memory performance (By similarity). In contrast to CPEB1, CPEB2 and CPEB4, not required for cell cycle progression (By similarity). [UniProtKB/Swiss-Prot Function] shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service. Performance OriGene guarantees that the sequences in the shRNA expression cassettes are verified to **Guaranteed:** 

correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US